The Future of Lethal Injection Is Being Debated at the Supreme Court. Read These 6 Stories Now.

<a href="http://www.istockphoto.com/portfolio/davidhills#58caa7c">David Hills</a>/iStock

Get your news from a source that’s not owned and controlled by oligarchs. Sign up for the free Mother Jones Daily.


Same-sex marriage is not the only major item on the Supreme Court’s docket this week: Today, the court will begin considering the future of a drug used in lethal injections. The suit, Glossip v. Gross, was brought by three Oklahoma inmates sentenced to death and challenges the use of the sedative Midazolam. The inmates’ lawyers argue that the drug—used in the botched execution of Clayton Lockett, who gasped for air and writhed in pain for a prolonged period as he was put to death—violates the Eighth Amendment’s protection from cruel and unusual punishment.

While only four states currently administer Midazolam, a Supreme Court ruling upholding its use could lead more states to employ the drug in executions. An opposite ruling could make lethal injection, and death penalty execution in general, rarer than it is now. Outlawing Midazolam, one of the few available lethal injection drugs, could leave states without any viable alternatives. Ahead of the oral arguments, read up on Mother Jones‘ best coverage of lethal injection and death penalty issues.

BEFORE YOU CLICK AWAY!

December is make or break for us. A full one-third of our annual fundraising comes in this month alone. A strong December means our newsroom is on the beat and reporting at full strength. A weak one means budget cuts and hard choices ahead.

The December 31 deadline is closing in fast. To reach our $400,000 goal, we need readers who’ve never given before to join the ranks of MoJo donors. And we need our steadfast supporters to give again today—any amount.

Managing an independent, nonprofit newsroom is staggeringly hard. There’s no cushion in our budget—no backup revenue, no corporate safety net. We can’t afford to fall short, and we can’t rely on corporations or deep-pocketed interests to fund the fierce, investigative journalism Mother Jones exists to do.

That’s why we need you right now. Please chip in to help close the gap.

BEFORE YOU CLICK AWAY!

December is make or break for us. A full one-third of our annual fundraising comes in this month alone. A strong December means our newsroom is on the beat and reporting at full strength. A weak one means budget cuts and hard choices ahead.

The December 31 deadline is closing in fast. To reach our $400,000 goal, we need readers who’ve never given before to join the ranks of MoJo donors. And we need our steadfast supporters to give again today—any amount.

Managing an independent, nonprofit newsroom is staggeringly hard. There’s no cushion in our budget—no backup revenue, no corporate safety net. We can’t afford to fall short, and we can’t rely on corporations or deep-pocketed interests to fund the fierce, investigative journalism Mother Jones exists to do.

That’s why we need you right now. Please chip in to help close the gap.

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate